Russian Federation
Chronic renal failure is one of the most significant problems of global health care, covering up to 10% of the world population. In the Russian Federation, the number of patients with this disease is estimated at 14 million people. The main risk factors for the development of chronic renal failure are obesity, arterial hypertension and smoking. The growing number of patients with CKD has significant socio-economic consequences. Key risk factors include aging, diabetes mellitus and obesity. Prevention of chronic kidney disease includes systematic health surveillance, increasing public awareness and improving access to health care. This article reviews the problem of chronic kidney disease in Russia and suggests ways to improve diagnosis and treatment.
chronic kidney disease, risk factors, prevention
1. Batyushin M. M. Hronicheskaya bolezn' pochek: sovremennoe sostoyanie problemy // Racional'naya farmakoterapiya v kardiologii. – 2020. – T. 16. – №. 6. – S. 938-947. DOIhttps://doi.org/10.20996/1819-6446-2020-1 1-06. DOI: https://doi.org/10.20996/1819-6446-2020-11-06; EDN: https://elibrary.ru/WHKBHV
2. Daminova K. M. i dr. Osobennosti ranney diagnostiki hronicheskoy bolezni pochek // Innovative developments and research in education. – 2023. – T. 2. – №. 13. – S. 179-186.
3. Murkamilov I. T. i dr. Sovremennye metody zamedleniya progressirovaniya hronicheskoy bolezni pochek pri saharnom diabete II tipa // Vestnik sovremennoy klinicheskoy mediciny. – 2020. – T. 13. – №. 4. – S. 76-85. DOI:https://doi.org/10.20969/VSKM.2020.13(4).76-85. EDN: https://elibrary.ru/UGKJZK
4. Ammirati A. L. Chronic kidney disease // Revista da Associação Médica Brasileira. – 2020. T. 66. – S 249. DOI:https://doi.org/10.1590/1806-9282.66.S1.3 EDN: https://elibrary.ru/DSKOMX
5. Carney E. F. The impact of chronic kidney disease on global health // Nature Reviews Nephrology. – 2020. – T. 16. – №. 5. – S. 251-252. DOI:https://doi.org/10.1038/s41581-020-0268-7
6. Charles C., Ferris A. H. Chronic kidney disease // Primary Care: Clinics in Office Practice. 2020. – T. 47. – №. 4. – S. 585-595. DOI:https://doi.org/10.1016/j.pop.2020.08.001
7. Cockwell P., Fisher L. A. The global burden of chronic kidney disease // The Lancet. – 2020. T. 395. – №. 10225. – S. 662-664. DOI:https://doi.org/10.1016/S0140-6736(19)32977-0 EDN: https://elibrary.ru/WUXAUR
8. EMPA-Kidney Collaborative Group. Empagliflozin in patients with chronic kidney disease // New England Journal of Medicine. – 2023. – T. 388. – №. 2. – S. 117-127. DOIhttps://doi.org/10.1056/NEJMoa2204233. EDN: https://elibrary.ru/QZEVHI
9. Jankowski J. et al. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options // Circulation. – 2021. – T. 143. – №. 11. – S. 1157-1172. DOIhttps://doi.org/10.1161/CIRCULATIONAHA.120.050686. EDN: https://elibrary.ru/AHSQSF
10. Kalantar-Zadeh K. et al. Chronic kidney disease // The lancet. – 2021. – T. 398. – №. 10302.– S. 786-802. DOI:https://doi.org/10.1016/S0140-6736(21)00519-5. EDN: https://elibrary.ru/TFVZJU
11. Kovesdy C. P. Epidemiology of chronic kidney disease: an update 2022 // Kidney international supplements. – 2022. – T. 12. – №. 1. – S. 7-11. DOI:https://doi.org/10.1016/j.kisu.2021.11.003 EDN: https://elibrary.ru/EPJEES
